logo

Five Prime Therapeutics (FPRX)



Trade FPRX now with
  Date
  Headline
9/10/2018 9:06:50 AM Five Prime Completes Phase 1 Safety Lead-In And Initiates Phase 3, Global Registrational Trial Of Bemarituzumab
8/10/2018 7:33:25 AM Wedbush Is Increasing Five Prime Therapeutics (FPRX) FY18 Rev. Estimate To 55.1 M From 32.5 M
8/10/2018 7:33:02 AM Wedbush Is Raising Five Prime Therapeutics (FPRX) FY19 Estimate To -4.19 From -4.61
8/10/2018 7:32:47 AM Wedbush Is Cutting Five Prime Therapeutics (FPRX) Q4 19 Estimate To -1.08 From -1.00
8/10/2018 7:32:35 AM Wedbush Is Raising Five Prime Therapeutics (FPRX) Q3 19 Estimate To -1.06 From -1.17
8/10/2018 7:32:23 AM Wedbush Is Raising Five Prime Therapeutics (FPRX) Q2 19 Estimate To -1.05 From -1.23
8/10/2018 7:32:11 AM Wedbush Is Raising Five Prime Therapeutics (FPRX) Q1 19 Estimate To -1.00 From -1.22
8/10/2018 7:31:56 AM Wedbush Is Raising Five Prime Therapeutics (FPRX) FY18 Estimate To -3.95 From -5.79
8/10/2018 7:31:40 AM Wedbush Is Raising Five Prime Therapeutics (FPRX) Q4 18 Estimate To -1.19 From -1.74
8/10/2018 7:31:28 AM Wedbush Is Increasing Five Prime Therapeutics (FPRX) Q3 18 Estimate To -1.14 From -1.71
5/31/2018 6:37:31 AM Intelligent Investor - May 31
5/17/2018 4:16:17 PM Wedbush Starts Five Prime Therapeutics (FPRX) At Neutral With $17 Price Target
5/15/2018 4:14:17 PM Five Prime Therapeutics Appoints Bryan Irving As Chief Scientific Officer
4/3/2018 7:14:56 AM Personal Genome Collaborates With Five Prime To Develop Plasma-based Companion Diagnostic Assay
3/28/2018 4:11:40 PM Five Prime Therapeutics Initiates Patient Dosing In Phase 1 Trial Of Novel First-in-Class B7-H4 Antibody FPA150
3/1/2018 11:23:58 AM Jefferies Is Increasing Five Prime Therapeutics (FPRX) 2019 Estimate To -4.26 From -5.33
3/1/2018 11:23:39 AM Jefferies Is Raising Five Prime Therapeutics (FPRX) 2018 Estimate To -4.33 From -6.65
3/1/2018 11:22:46 AM Jefferies Is Raising Five Prime Therapeutics (FPRX) 2018 Rev. Estimate To 60.0 M From 30.0 M